Clinical Trials Search
Clinical Trial 18361
Cancer Type: Malignant Hematology
Interventions:Adcetris (Brentuximab vedotin); Adriamycin (doxorubicin); Brentuximab vedotin; DTIC (Dacarbazine); Dacarbazine; SGN-35 (Brentuximab vedotin)
Study Type: Treatment
Phase of Study: Phase II
- Celeste Bello
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
The purpose of this study is to see whether brentuximab in combination with Adriamycin and Dacarbazine (AD) is effective in treating Hodgkin Lymphoma.
Primary Objective: To investigate the clinical activity of Brentuximab with AD in untreated non-bulky stage I and II Classical Hodgkin Lymphoma (cHL). Secondary Objective: To describe the safety and tolerability of Brentuximab combined with AD in previously untreated non-bulky limited stage cHL.